Program
olaparib
Also written as “Olaparib”, “AZD2281” and “KU-0059436 (AZD2281)(PARP inhibitor)”.
Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Prostatic Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 6 companies.
Drug pageOlaparib: every studyMany companies study it; this page follows only the 76 they lead. All 323 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 5915 open or running | phase 4since Jun 10, 2015 | Jun 27, 2007 | Apr 6, 2027phase 3 · NCT04421963 |
| Merckits history only | 125 open or running | phase 3since Mar 29, 2018 | Aug 3, 2016 | May 5, 2027phase 3 · NCT04380636 |
| Novartis | 20 open or running | phase 3since Jan 25, 2021 | Jan 25, 2021 | none ahead |
| Boryung Pharmaceuticalits history only | 11 open or running | phase 1since Jul 7, 2025 | Jul 7, 2025 | none ahead |
| CSPC Pharmaceutical Groupits history only | 10 open or running | phase 1since Apr 7, 2024 | Apr 7, 2024 | none ahead |
| Daewoong Pharmaceuticalits history only | 11 open or running | phase 1since Jan 19, 2026 | Jan 19, 2026 | Mar 2027phase 1 · NCT07371104 |
Also a collaborator on its studies: Myriad Genetic Laboratories, Frontier Science & Technology Research Foundation, Hoffmann-La Roche, Myriad Genetics, Iqvia Pty, Covance, Theradex, Parexel and KuDOS Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 25, 2021First study: phase 3 study in Ovarian NeoplasmsFirst studyNCT04729387 · 358 enrolled · United States, Argentina, Australia and more
- Feb 17, 2022Phase 1 study in Ovarian NeoplasmsNCT05258747 · 70 enrolled · India
TargetBeta
“PARP 1, 2 and 3 inhibitor”ChEMBL 37, by rule
Studies
All 2 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05258747Ovarian Neoplasms · India | 1 | Completed | Oct 20, 2022 | 70 |
| NCT04729387Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Apr 21, 2023 | 358 |
How it is read
Names in the registry
- “Olaparib”, 38 entries
- “olaparib”, 10 entries
- “AZD2281”, 10 entries
- “KU-0059436 (AZD2281)(PARP inhibitor)”, 10 entries
- “Olaparib 300mg tablets”, 3 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 24 studies
- Breast Neoplasms, 7 studies
- Prostatic Neoplasms, 7 studies
- Neoplasms, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.